Binding Site presents data on new Combylite assay

Binding Site has presented data on a newly-developed assay product called Combylite, which can potentially be used in the diagnosis of several diseases.

At the recent International Symposium on Serum Free Light Chain Analysis meeting in Bath, Binding Site's research and development director Dr Graham Mead provided details of the assay, which is available for research use this month.

Combylite is a single assay that measures the combined level of free kappa and free lambda immunoglobulin light chains and has been designed as a companion to the manufacturer's current Freelite and Heavylite offerings.

According to Binding Site's research, the device can be used to effectively measure combined free light chain levels for a variety of disorders, including chronic kidney disease and liver disease.

The company said: "With the companion Freelite and Hevylite products, it would appear that Binding Site once again have come up with another first in protein assays."

Earlier this month, Binding Site appointed diagnostics industry veteran Charles de Rohan as its new chief executive officer.